[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335211-105":59,"doc-detail-335211-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cancer-therapy-resistance-mediated-by-cancer-associated-fibroblast-derived-extracellular-vesicles-biological-mechanisms-to-clinical-significance-and-implications-review","Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles - biological mechanisms to clinical significance and implications - Review","","Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles examines how cancer-associated fibroblasts (CAFs) in the tumor microenvironment shape cancer progression and patient prognosis. CAFs regulate tumor behavior through extracellular vesicles (EVs), secreted factors, and metabolites, with CAF-derived EVs acting as key mediators of resistance. The review consolidates biological roles and molecular mechanisms linking CAF-derived EVs to resistance against chemotherapy, targeted therapy, radiotherapy, and immunotherapy, and evaluates their value as novel therapeutic targets and clinical biomarkers to improve treatment efficacy and outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-therapy-resistance-mediated-by-cancer-associated-fibroblast-derived-extracellular-vesicles-biological-mechanisms-to-clinical-significance-and-implications-review/335211/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-therapy-resistance-mediated-by-cancer-associated-fibroblast-derived-extracellular-vesicles-biological-mechanisms-to-clinical-significance-and-implications-review/335211.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role do cancer-associated fibroblasts (CAFs) play in cancer progression and prognosis?","Question",{"text":113,"@type":114},"CAFs are a diverse stromal cell population in the tumor microenvironment that fundamentally contributes to cancer progression and influences patient prognosis by regulating tumor behaviors.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do CAF-derived extracellular vesicles (EVs) relate to cancer therapy resistance?",{"text":118,"@type":114},"CAF-derived EVs are identified as critical mediators of cancer therapy resistance, acting as novel therapy targets and biomarkers in cancer management.",{"name":120,"@type":111,"acceptedAnswer":121},"Which cancer treatments does the review focus on regarding CAF-derived EV-driven resistance?",{"text":122,"@type":114},"The review summarizes mechanisms behind resistance to chemotherapy, targeted therapy, radiotherapy, and immunotherapy, and discusses clinical implications for enhancing therapy efficacy.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},335211,1790014837,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Lin etal. Molecular Cancer (2024) 23:191 [https://doi.org/10.1186/s12943-024-02106-8](https://doi.org/10.1186/s12943-024-02106-8)  \nMolecular Cancer  \n REVIEW Open Access  \nCancer therapy resistance mediated   by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications  \nZhengjun Lin1,2†, Guoqing Li1,2†, Ke Jiang1,3, Zhihong Li1* and Tang Liu 1*  \nAbstract  \nCancer-associated fibroblasts (CAFs) are a diverse stromal cell population within the tumour microenvironment, where they play fundamental roles in cancer progression and patient prognosis. Multiple lines of evidence have identified that CAFs are critically involved in shaping the structure and function of the tumour microenvironment with numerous functions in regulating tumour behaviours, such as metastasis, invasion, and epithelial-mesenchymal transition (EMT) . CAFs can interact extensively with cancer cells by producing extracellular vesicles (EVs), multiple secreted factors, and metabolites. Notably, CAF-derived EVs have been identified as critical mediators of cancer therapy resistance, and constitute novel therapy targets and biomarkers in cancer management. This review aimed to summarize the biological roles and detailed molecular mechanisms of CAF-derived EVs in mediating cancer resistance to chemotherapy, targeted therapy agents, radiotherapy, and immunotherapy. We also discussed the therapeutic potential of CAF-derived EVs as novel targets and clinical biomarkers in cancer clinical management, thereby providing a novel therapeutic strategy for enhancing cancer therapy efficacy and improving patient prognosis. Keywords Cancer-associated fibroblasts, Extracellular vesicles, Therapy resistance, Clinical biomarker  \n†Zhengjun Lin and Guoqing Li contributed equally to this work and share the first authorship.  \n*Correspondence: Zhihong Li[lizhihong@csu.edu.cn](lizhihong@csu.edu.cn)[ ](lizhihong@csu.edu.cn)Tang Liu [liutang1204@csu.edu.cn](liutang1204@csu.edu.cn)  \n1 Department of Orthopedics, The Second Xiangya Hospital, Central South University, 139\\# Middle Renmin Road, Changsha, Hunan Province 410011, China  \n2 Xiangya School of Medicine, Central South University, Changsha 410013, Hunan Province, China  \n3 Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410078, China  \nIntroduction  \nCancer continues to be a serious public health challenge affecting people worldwide [1, 2]. Despite the substantial investment in cancer research and the extensive array of anti-cancer treatments available, therapy resistance remains the most serious factor impeding therapeutic efficacy [3, 4]. The intricate panorama of cancer therapy resistance entails multifaceted mechanisms such as altered drug uptake and efflux, inhibition of apoptosis signaling pathways, activation of cancer stem cells (CSCs), enhanced DNA repair capacities, disrupted cell cycle regulation, and physical obstacles impairing drug penetration and efficacy [5–7]. Nowadays, multiple ongoing studies have explored new drugs and combinations to address therapy resistance. For instance, bufalin, a compound found in secretions from the glands of toads  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons lice","cbCaieBe4joNUOHY","https://ap.wps.com/l/cbCaieBe4joNUOHY","pdf",2498129,18,"English","# Abstract\n## Cancer-associated fibroblasts and tumor microenvironment\n## Extracellular vesicles as mediators of resistance\n## Resistance across therapy types\n## Therapeutic and biomarker implications\n# Introduction\n## Therapy resistance as a major barrier\n## Mechanistic landscape of therapy resistance\n## Role of tumor microenvironment and non-tumor cells\n## CAF origins and functions","[{\"question\":\"What role do cancer-associated fibroblasts (CAFs) play in cancer progression and prognosis?\",\"answer\":\"CAFs are a diverse stromal cell population in the tumor microenvironment that fundamentally contributes to cancer progression and influences patient prognosis by regulating tumor behaviors.\"},{\"question\":\"How do CAF-derived extracellular vesicles (EVs) relate to cancer therapy resistance?\",\"answer\":\"CAF-derived EVs are identified as critical mediators of cancer therapy resistance, acting as novel therapy targets and biomarkers in cancer management.\"},{\"question\":\"Which cancer treatments does the review focus on regarding CAF-derived EV-driven resistance?\",\"answer\":\"The review summarizes mechanisms behind resistance to chemotherapy, targeted therapy, radiotherapy, and immunotherapy, and discusses clinical implications for enhancing therapy efficacy.\"}]","Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles - biological mechanisms to clinical significance and implications - Review | PDF",1790010171,45]